UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 73.

Wick, W; Roth, P; Hartmann, C; Hau, P; Nakamura, M; Stockhammer, F; Sabel, M C; Wick, A; Koeppen, S; Ketter, R; Vajkoczy, P; Eyupoglu, I; Kalff, R; Pietsch, T; Happold, C; Galldiks, N; Schmidt-Graf, F; Bamberg, M; Reifenberger, G; Platten, M; von Deimling, A; Meisner, C; Wiestler, B; Weller, M (2016). Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro-Oncology, 18(11):1529-1537.

Weiss, T; Weller, M; Roth, P (2016). Immunological effects of chemotherapy and radiotherapy against brain tumors. Expert Review of Anticancer Therapy, 16(10):1087-1094.

Happold, C; Gorlia, T; Chinot, O; Gilbert, M R; Nabors, L B; Wick, W; Pugh, S L; Hegi, M; Cloughesy, T; Roth, P; Reardon, D A; Perry, J R; Mehta, M P; Stupp, R; Weller, M (2016). Reply to F. Felix et al and M.F. Fay et al. Journal of Clinical Oncology, 34(25):3107-3108.

Strehlow, F; Bauer, S; Martus, P; Weller, M; Roth, P; Schlegel, U; Seidel, S; Scheibenbogen, C; Korfel, A; Kreher, S (2016). Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma. Journal of Neuro-Oncology, 129(1):165-171.

Burgett, M E; Lathia, J D; Roth, P; Nowacki, A S; Galileo, D S; Pugacheva, E; Huang, P; Vasanji, A; Li, M; Byzova, T; Mikkelsen, T; Bao, S; Rich, J N; Weller, M; Gladson, C L (2016). Direct contact with perivascular tumor cells enhances integrin αvβ3 signaling and migration of endothelial cells. OncoTarget:43852-43867.

Backes, C; Meder, B; Hart, M; Ludwig, N; Leidinger, P; Vogel, B; Galata, V; Roth, P; Menegatti, J; Grässer, F; Ruprecht, K; Kahraman, M; Grossmann, T; Haas, J; Meese, E; Keller, A (2016). Prioritizing and selecting likely novel miRNAs from NGS data. Nucleic Acids Research, 44(6):e53.

Gulden-Sala, W; Roth, P; Brown, M; Andratschke, N; Weller, M; Stupp, R (2016). Gliome – was ich wissen muss in zehn Fragen. Praxis, 105(6):330-337.

Stojcheva, Nina; Schechtmann, G; Sass, S; Roth, P; Florea, A M; Stefanski, A; Stühler, K; Wolter, M; Müller, N S; Theis, F J; Weller, M; Reifenberger, G; Happold, C (2016). MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM. OncoTarget, 7(11):12937-12950.

Happold, C; Gorlia, T; Chinot, O; Gilbert, M R; Nabors, L B; Wick, W; Pugh, S L; Hegi, M; Cloughesy, T; Roth, P; Reardon, D A; Perry, J R; Mehta, M P; Stupp, R; Weller, M (2016). Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. Journal of Clinical Oncology, 34(7):731-739.

Codó, P; Weller, M; Kaulich, K; Schraivogel, D; Silginer, M; Reifenberger, G; Meister, G; Roth, P (2016). Control of glioma cell migration and invasiveness by GDF-15. OncoTarget, 7(7):7732-7746.

Roelcke, U; Wyss, M T; Nowosielski, M; Rudà, R; Roth, P; Hofer, S; Galldiks, N; Crippa, F; Weller, M; Soffietti, R (2016). Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas. Neuro-Oncology, 18(5):744-751.

Gramatzki, Dorothee; Roth, P; Felsberg, J; Hofer, S; Rushing, E J; Hentschel, B; Westphal, M; Krex, D; Simon, M; Schnell, O; Wick, W; Reifenberger, G; Weller, M (2016). Chemotherapy for intracranial ependymoma in adults. BMC Cancer, 16(1):287.

Roth, P; Preusser, M; Weller, M (2016). Immunotherapy of Brain Cancer. Oncology Research and Treatment, 39(6):326-334.

Hundsberger, T; Hottinger, A F; Roelcke, U; Roth, P; Migliorini, D; Dietrich, P Y; Conen, K; Pesce, G; Hermann, E; Pica, A; Gross, M W; Brügge, D; Plasswilm, L; Weller, M; Putora, P M (2016). Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes. Journal of Neuro-Oncology, 126(1):175-183.

Silginer, M; Burghardt, I; Gramatzki, D; Bunse, L; Leske, H; Rushing, E J; Hao, N; Platten, M; Weller, M; Roth, P (2016). The aryl hydrocarbon receptor links integrin signaling to the TGF-β pathway. Oncogene, 35(25):3260-3271.

Roth, P; Keller, A; Hoheisel, J D; Codo, P; Bauer, A S; Backes, C; Leidinger, P; Meese, E; Thiel, E; Korfel, A; Weller, M (2015). Differentially regulated miRNAs as prognostic biomarkers in the blood of primary CNS lymphoma patients. European Journal of Cancer, 51(3):382-390.

Preusser, M; Roth, P (2015). New frontiers in neurooncology. Current Opinion in Neurology, 28(6):626-627.

Wirsching, H G; Happold, C; Roth, P; Weller, M (2015). Management of diffusely infiltrating glioma in the elderly. Current Opinion in Oncology, 27(6):502-509.

Weiss, T; Weller, M; Roth, P (2015). Immunotherapy for glioblastoma: concepts and challenges. Current Opinion in Neurology, 28(6):639-646.

Roth, P; Weller, M (2015). Management of neoplastic meningitis. Chinese Clinical Oncology, 4(2):26.

Roth, P; Weller, M (2015). Chemotherapie von Hirntumoren bei Erwachsenen. Der Nervenarzt, 86(4):495-508.

Kreher, S; Jöhrens, K; Strehlow, F; Martus, P; Borowiec, K; Radke, J; Heppner, F; Roth, P; Thiel, E; Pietsch, T; Weller, M; Korfel, A (2015). Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma. Neuro-Oncology, 17(7):1016-1021.

Korfel, A; Thiel, E; Martus, P; Möhle, R; Griesinger, F; Rauch, Mi; Röth, A; Hertenstein, B; Fischer, T; Hundsberger, T; Mergenthaler, H G; Junghanß, C; Birnbaum, T; Fischer, L; Jahnke, K; Herrlinger, U; Roth, P; Bamberg, M; Pietsch, T; Weller, M (2015). Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology, 84(12):1242-1248.

Roth, P; Happold, C; Weller, M (2015). Corticosteroid use in neuro-oncology: an update. Neuro-Oncology Practice, 2(1):6-12.

Lassen, U; Chinot, O L; McBain, C; Mau-Sørensen, M; Larsen, V A; Barrie, M; Roth, P; Krieter, O; Wang, K; Habben, K; Tessier, J; Lahr, A; Weller, M (2015). Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. Neuro-Oncology, 17(7):1007-1015.

Wolpert, F; Happold, C; Reifenberger, G; Florea, A M; Deenen, R; Roth, P; Neidert, M C; Lamszus, K; Westphal, M; Weller, M; Eisele, G (2015). Interferon-β modulates the innate immune response against glioblastoma initiating cells. PLoS ONE, 10(10):e0139603.

Kreher, S; Strehlow, F; Martus, P; Roth, P; Hertenstein, B; Röth, A; Birnbaum, T; Griesinger, F; Rauch, M; Kanz, L; Thiel, E; Weller, M; Korfel, A (2015). Prognostic impact of intraocular involvement in primary CNS lymphoma: experience from the G-PCNSL-SG1 trial. Annals of Hematology, 94(3):409-414.

Roth, P; Hoang-Xuan, K (2014). Challenges in the treatment of elderly patients with primary central nervous system lymphoma. Current Opinion in Neurology, 27(6):697-701.

Ahmad, M; Frei, K; Willscher, E; Stefanski, A; Kaulich, K; Roth, P; Stühler, K; Reifenberger, G; Binder, H; Weller, M (2014). How stemlike are sphere cultures from long-term cancer cell lines? Lessons from mouse glioma models. Journal of Neuropathology and Experimental Neurology, 73(11):1062-1077.

Roth, P; Weller, M (2014). Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies. Neuro-Oncology, 16(suppl 8):viii14-viii19.

Codo, P; Weller, M; Meister, G; Szabo, E; Steinle, A; Wolter, M; Reifenberger, G; Roth, P (2014). MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape. OncoTarget, 5(17):7651-7662.

Hundsberger, T; Roth, P; Roelcke, U (2014). Neurologische Komplikationen bei onkologischen Patienten. Praxis, 103(17):1009-1016.

Wiestler, B; Capper, D; Sill, M; Jones, D T W; Hovestadt, V; Sturm, D; Koelsche, C; Bertoni, A; Schweizer, L; Korshunov, A; Weiß, E K; Schliesser, M G; Radbruch, A; Herold-Mende, C; Roth, P; Unterberg, A; Hartmann, C; Pietsch, T; Reifenberger, G; Lichter, P; Radlwimmer, B; Platten, M; Pfister, S M; von Deimling, A; Weller, M; Wick, W (2014). Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathologica, 128(4):561-571.

Tonder, M; Weller, M; Eisele, G; Roth, P (2014). Carboplatin and Etoposide in Heavily Pretreated Patients with Progressive High-Grade Glioma. Chemotherapy, 60(5-6):375-378.

Silginer, M; Weller, M; Ziegler, U; Roth, P (2014). Integrin inhibition promotes atypical anoikis in glioma cells. Cell Death and Disease, 5:e1012.

Happold, C; Roth, P; Silginer, M; Florea, A M; Lamszus, K; Frei, K; Deenen, R; Reifenberger, G; Weller, M (2014). Interferon-β induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells. Molecular Cancer Therapeutics, 13(4):948-961.

Rossetti, A O; Jeckelmann, S; Novy, J; Roth, P; Weller, M; Stupp, R (2014). Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study. Neuro-Oncology, 16(4):584-588.

Brown, M; Roth, P (2014). Oligodendrogliome - Interdisziplinäre Therapie ist erforderlich. info@onkologie, 4(2):24-26.

Roth, P; Stupp, R; Eisele, G; Weller, M (2014). Treatment of primary CNS lymphoma. Current Treatment Options in Neurology, 16(1):277.

Roth, P. Molecular mechanisms of glioma immune escape. 2013, University of Zurich, Faculty of Medicine.

Roth, P; Wick, W; Weller, M (2013). Anaplastic Oligodendroglioma: A New Treatment Paradigm and Current Controversies. Current Treatment Options in Oncology, 14(4):505-513.

Roth, P; Silginer, M; Goodman, S L; Hasenbach, K; Thies, S; Maurer, G; Schraml, P; Tabatabai, G; Moch, H; Tritschler, I; Weller, M (2013). Integrin control of the transforming growth factor-β pathway in glioblastoma. Brain, 136(2):564-576.

Hundsberger, T; Roth, P (2013). Neuroonkologie – ASCO 2013: Erst- und Rezidivbehandlung von Glioblastomen – Ernüchterung durch negative Phase-III-Studien. Leading Opinions Neurologie & Psychiatrie:1-3.

Roth, P; Regli, L; Tonder, M; Weller, M (2013). Tumor-associated edema in brain cancer patients: pathogenesis and management. Expert Review of Anticancer Therapy, 13(11):1319-1325.

Vogetseder, A; Thies, S; Ingold, B; Roth, P; Weller, M; Schraml, P; Goodman, S L; Moch, H (2013). αv-Integrin isoform expression in primary human tumors and brain metastases. International Journal of Cancer, 133(10):2362-2371.

Happold, C; Roth, P; Wick, W; Schmidt, N; Florea, A M; Silginer, M; Reifenberger, G; Weller, M (2012). Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. Journal of Neurochemistry, 122(2):444-455.

Wolpert, F; Roth, P; Lamszus, K; Tabatabai, G; Weller, M; Eisele, G (2012). HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells. Journal of Neuroimmunology, 250(1-2):27-34.

Roth, P; Eisele, G; Weller, M (2012). Immunology of brain tumors. In: Aminoff, M; Boller, F; Swaab, D. Neuro-Oncology. Amsterdam: Elsevier, 45-51.

Roth, P; Martus, P; Kiewe, P; Mohle, R; Klasen, H; Rauch, M; Roth, A; Kaun, S; Thiel, E; Korfel, A; Weller, M (2012). Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial. Neurology, 79(9):890-896.

Roth, P; Korfel, A; Martus, P; Weller, M (2012). Pathogenesis and management of primary CNS lymphoma. Expert Review of Anticancer Therapy, 12(5):623-633.

Korfel, A; Weller, M; Martus, P; Roth, P; Klasen, H A; Roeth, A; Rauch, M; Hertenstein, B; Fischer, T; Hundsberger, T; Leithäuser, M; Birnbaum, T; Kirchen, H; Mergenthaler, H G; Schubert, J; Berdel, W; Birkmann, J; Hummel, M; Thiel, E; Fischer, L (2012). Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL): experience from the G-PCNSL-SG1 trial. Annals of Oncology, 23(9):2374-2380.

Weller, M; Martus, P; Roth, P; Thiel, E; Korfel, A (2012). Surgery for primary CNS lymphoma? Challenging a paradigm. Neuro-Oncology, 14(12):1481-1484.

Eisele, G; Roth, P; Hasenbach, K; Aulwurm, S; Wolpert, F; Tabatabai, G; Wick, W; Weller, M (2011). APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. Neuro-Oncology, 13(2):155-164.

Roth, P; Wischhusen, J; Happold, C; Chandran, P A; Hofer, S; Eisele, G; Weller, M; Keller, A (2011). A specific miRNA signature in the peripheral blood of glioblastoma patients. Journal of Neurochemistry, 118(3):449-457.

Weller, M; Platten, M; Roth, P; Wick, W (2011). Geriatric neuro-oncology: from mythology to biology. Current Opinion in Neurology, 24(6):599-604.

El-Beltagy, M; Muroi, C; Roth, P; Fandino, J; Imhof, H G; Yonekawa, Y (2010). Recurrent intracranial aneurysms after successful neck clipping. World Neurosurgery, 74(4-5):472-477.

Roth, P; Junker, M; Tritschler, I; Mittelbronn, M; Dombrowski, Y; Breit, S N; Tabatabai, G; Wick, W; Weller, M; Wischhusen, J (2010). GDF-15 contributes to proliferation and immune escape of malignant gliomas. Clinical Cancer Research, 16(5):3851-3859.

Kurzwelly, D; Glas, M; Roth, P; Weimann, E; Lohner, H; Waha, A; Schabet, M; Reifenberger, G; Weller, M; Herrlinger, U (2010). Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. Journal of Neuro-Oncology, 97(3):389-392.

Grisariu, S; Avni, B; Batchelor, T T; van den Bent, M J; Bokstein, F; Schiff, D; Kuittinen, O; Chamberlain, M C; Roth, P; Nemets, A; Shalom, E; Ben-Yehuda, D; Siegal, T (2010). Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report. Blood, 115(24):5005-5011.

Miller, J; Eisele, G; Tabatabai, G; Aulwurm, S; von Kürthy, G; Stitz, L; Roth, P; Weller, M (2010). Soluble CD70: a novel immunotherapeutic agent for experimental glioblastoma. Journal of Neurosurgery, 113(2):280-285.

Roth, P; Wick, W; Weller, M (2010). Steroids in neurooncology: actions, indications, side-effects. Current Opinion in Neurology, 23(6):597-602.

Yaşargil, M G; Krayenbühl, N; Roth, P; Hsu, S P; Yaşargil, D C (2010). The selective amygdalohippocampectomy for intractable temporal limbic seizures. Journal of Neurosurgery, 112(1):168-185.

Wick, W; Roth, P; Wick, A; Weller, M (2010). Was gibt es Neues in der Neuroonkologie. Aktuelle Neurologie, 37(9):454-460.

Roth, P; Weller, M (2009). Comments : Dendritic-cell- and peptide-based vaccination strategies for glioma. Neurosurgical Review, 32(3):273.

Roth, T; Sokolov, A N; Messias, A; Roth, P; Weller, M; Trauzettel-Klosinski, S (2009). Comparing explorative saccade and flicker training in hemianopia: a randomized controlled study. Neurology, 72(4):324-331.

Roth, P; Kissel, M; Herrmann, C; Eisele, G; Leban, J; Weller, M; Schmidt, F (2009). SC68896, a novel small molecule proteasome inhibitor, exerts antiglioma activity in vitro and in vivo. Clinical Cancer Research, 15(21):6609-6618.

Roth, P; Zumsteg, D (2009). Seizure-induced periorbital petechial rash. European Neurology, 61(5):317.

Happold, C; Ernemann, U; Roth, P; Wick, W; Weller, M; Schmidt, F (2008). Anticoagulation for radiation-induced neurotoxicity revisited. Journal of Neuro-Oncology, 90(3):357-362.

Zumofen, D; Khan, N; Roth, P; Samma, A; Yonekawa, Y (2008). Bonnet bypass in multiple cerebrovascular occlusive disease. In: Yonekawa, Y; Tsukahara, T; Valavanis, A; Khan, N. Changing Aspects in Stroke Surgery: Aneurysms, Dissections, Moyamoya Angiopathy and EC-IC Bypass. Austria - Wien, 2008: Springer Viena, 103-107.

Yonekawa, Y; Zumofen, D; Imhof, H G; Roth, P; Khan, N (2008). Hemorrhagic cerebral dissecting aneurysms: surgical treatments and results. In: Yonekawa, Y; Tsukahara, T; Valavanis, A; Khan, N. Changing Aspects in Stroke Surgery: Aneurysms, Dissections, Moyamoya Angiopathy and EC-IC Bypass. Austria - Wien, 2008: Springer Viena, 61-69.

Eisele, G; Roth, P; Wick, W; Weller, M (2008). MGMT in der klinischen Praxis. Onkologie Heute, 6(4):32-39.

Otani, N; Fujioka, M; Oracuioglu, B; Muroi, C; Khan, N; Roth, P; Yonekawa, Y (2008). Thalamic cavernous angioma: paraculminar supracerebellar infratentorial transtentorial approach for the safe and complete surgical removal. In: Yonekawa, Y; Tsukahara, T; Valavanis, A; Khan, N. Changing Aspects in Stroke Surgery: Aneurysms, Dissections, Moyamoya Angiopathy and EC-IC Bypass. Austria - Wien, 2008: Springer Viena, 29-36.

Roth, P; Steiger, J (2006). Die Zürcher Bewegung. Focus das Magazin von Gesundheitsförderung Schweiz, (28):6-10.

This list was generated on Sat Jul 22 11:49:42 2017 CEST.